
    
      The study is designed as a prospective, single-arm, nonrandomized, open-label, phase I/II
      trial of radiation therapy (RT) followed by intrathecal (IT) trastuzumab/pertuzumab in the
      management of HER2+ breast leptomeningeal disease (LMD). Treatment will be initiated with RT,
      whole brain RT (WBRT) and/or focal brain/spine RT followed by IT trastuzumab/pertuzumab.
    
  